ClinicalTrials.gg
Status unknownNCT03328312Updated Nov 1, 2017

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

An Early Phase 1 interventional study of Sugammadex and neostigmine+atropine in Incidence of Postoperative Residual Curarization, sponsored by Iuliu Hatieganu University of Medicine and Pharmacy. Status unknown. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-11-01.

Sponsored by Iuliu Hatieganu University of Medicine and Pharmacy · Early Phase 1, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Oct 2017), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
16 Years to 65 Years
Sex
All
01

Study summary

Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining efficacy of reversal in obese patients.

Read the detailed description

Background Neuromuscular paralysis is a frequent requirement to facilitate airway management and surgery. Patients receiving neuromuscular blocking agents (NMBAs) are at risk of residual neuromuscular blockade (RNMB) that can lead to postoperative cardio-pulmonary complications, and may increase postoperative morbidity and mortality.1-2 NMBAs can be antagonized with the cholinesterase inhibitor neostigmine; however, this agent has several undesirable side effects because of its parasympathetic stimulation.3 Thus, muscarinic receptor antagonists, such as atropine, are used along with cholinesterase inhibitors; however, these drugs also have their own set of adverse effects. Despite its relatively slow onset of action and inability to antagonize profound blockade, neostigmine is still used frequently for reversal of rocuronium-induced neuromuscular blockade because of its low cost. Sugammadex is a selective relaxant biding agent, developed to encapsulate the steroidal NMBAs, and proved to be extremely effective for the reversal of either shallow (dose of 2 mg/kg), deep (dose of 4 mg/kg), or even profound (dose of 16 mg/kg) neuromuscular blockade. However, routine use of sugammadex is limited by its relatively high cost compared with neostigmine.

The purpose of the study is to investigate drug costs and adverse effects of low-dose neostigmine (0.025 mg/kg) plus low-dose sugammadex (1 mg/kg) for reversal of rocuronium-induced neuromuscular block, and compare efficacy of antagonism and costs of this combination therapy with the current standard therapies: full-dose sugammadex (2 mg/kg) and full-dose neostigmine (0.05 mg/kg) plus atropine.

Randomization and blinding On randomization, each patient will be allocated by a unique identifying number into study groups "A", "B", or "C". The allocation of a patient to the specific group will be only known by the research assistant. The participating anaesthetists as well as the research staff who collect patient data will remain blinded until after the completion of the study.

For reversal of rocuronium neuromuscular- block we used:

  • Group A - Sugammadex (Bridion®) 2 mg/kg,
  • Group B - Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.
  • Group C - Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.

Monitoring the neuromuscular blockade After induction of anesthesia and before administration of rocuronium, monitoring of neuromuscular blockade at the adductor pollicis muscle is initiated using acceleromyography (TOF-Watch SX, Organon, Dublin, Ireland). After degreasing the skin, two surface electrodes are placed above the ulnar nerve near the wrist. After induction of general anesthesia, 50-Hz tetanic stimulation is applied for 5 sec and followed after 1 min by train-of-four (TOF) stimulation every 15 sec. If the response to TOF is stable, calibration and supramaximal stimulation are ensured by built-in calibration function (CAL2). After at least 2 min of a stable baseline documentation of the response to TOF, rocuronium is administered.

At the end of surgery, inhalational agent (sevoflurane) will be discontinued. Once the end-tidal concentration of sevoflurane reaches 0.4-0.6%, the previously randomized reversal study drug will be administrated at shallow neuromuscular block (TOF count of 2). The primary efficacy variable is the incidence of residual neuromuscular block (defined as TOFR \<0.90) measured at least 15 min. after the administration of the reversal agent. In case of residual block, a rescue dose of 2 mg/kg sugammadex will be administrated before tracheal extubation. Extubation is performed once patient is deemed fully recovered (TOFR = 1.0)

02

Conditions studied

  • Incidence of Postoperative Residual Curarization
03

In context

Lead sponsor

Iuliu Hatieganu University of Medicine and Pharmacy is the lead sponsor of 56 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled for elective abdominal surgery
  • 16-65 years of age
  • 30-39.9 ( obese class I-II)
  • (ASA) physical status II.
  • Surgery scheduled for general anesthesia and tracheal intubation and planned extubation at the end of surgery
  • Surgical procedures with an anticipated length of at least 60 min.

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery

    • Patients unable to consent to study participation
    • Patients expected to be maintained on mechanical ventilation postoperatively
    • to any of the study drugs
    • Patients with existing neuromuscular disease
    • Acute or chronic renal failure (-EPI \<30 mL/min/1.73 m2)
    • Acute/chronic liver disease ( Score >1)
    • Hyperkalemia (> 5.3 mmol/l)
    • Pregnancy
    • History of stroke or ongoing paresis
    • Glaucoma
    • Breast feeding
    • Sepsis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Sugammadex

    For reversal of rocuronium neuromuscular- block we will use Sugammadex

    Drug: Sugammadex

  • Placebo comparator
    neostigmine+atropine

    For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.05 mg/kg and atropine 1 mg/ dose.

    Drug: neostigmine+atropine

  • Experimental
    neostigmine+atropine+sugammadex

    For reversal of rocuronium neuromuscular- block we will use Neostigmine (Miostin®; Stigmosan®) 0.025 mg/kg and atropine 0.5 mg/dose followed within 3 min by Sugammadex 1 mg/kg.

    Drug: neostigmine+atropine+sugammadex

Interventions

  • Time period from administration of the reversal agent to recovery of TOFR \>0.9

  • Drugneostigmine+atropine

    Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation

  • Drugneostigmine+atropine+sugammadex

    Drug pages: Neostigmine · Atropine · Sugammadex

    4. Time of extubation

06

What researchers measure

Primary outcomes

  1. Incidence of postoperative residual curarization (PORC)

    Incidence of postoperative residual curarization (PORC) (defined as a train-of-four ratio, TOFR \<0.9) measured 15 min after administration of the reversal agent.

    Time frame: 24 hours

Secondary outcomes

  1. Time

    1. Time period from administration of the reversal agent until recovery of TOFR to \>0.90

    Time frame: 24 hours

  2. Bradycardia

    2. Number of bradycardic episodes (HR \<60 bpm).

    Time frame: 24 hours

  3. Residual blockade

    3. Incidence of clinical symptoms potentially associated with residual neuromuscular blockade (diplopia, difficulty swallowing, feeling of general weakness)

    Time frame: 24 hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2017; primary completion for Mar 2018, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Nov 1, 2017
StartEst.
Dec 1, 2017
Primary completionEst.
Mar 1, 2018
CompletionEst.
Jun 1, 2018
Last update
Nov 1, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 1, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03328312
Lead sponsor
Iuliu Hatieganu University of Medicine and Pharmacy
Responsible party
Breazu Caius Mihai (Assistant professor MD,PhD, Iuliu Hatieganu University of Medicine and Pharmacy) — Principal investigator
First posted
Nov 1, 2017
Start date
Dec 1, 2017 (estimated)
Primary completion
Mar 1, 2018 (estimated)
Completion
Jun 1, 2018 (estimated)
Last update
Nov 1, 2017

Study contacts

Calin I Mitre, MD,PhD
Contact
cmitre2001@gmail.com
004074157497
Caius M Breazu, MD,PhD
Contact
csbreazu@yahoo.com
0040743010012
Caius Breazu, Md,PhD
principal investigator · Iuliu Hatieganu University of medicine and pharmacy cluj-Napoca

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Neostigmine · Atropine · Sugammadex

Start the discussion